Prolog Pharmaceuticals: Net profit in 2025 is expected to decrease by 13.62% year-over-year, with a proposed dividend of 2.38 yuan per 10 shares

NightAirdropper

2026-03-20 23:24:35

Abstract generation in progress

Gelonghui, March 19 — Prolor Pharmaceutical (000739.SZ) announced that in 2025, the company achieved operating revenue of 9.784 billion yuan, a year-on-year decrease of 18.62%; net profit attributable to shareholders of the listed company was 891 million yuan, down 13.62% year-on-year. The company plans to distribute a cash dividend of 2.38 yuan (including tax) for every 10 shares based on 1,127,631,276 shares, without issuing additional shares or increasing capital through reserves. During the reporting period, CDMO business revenue increased by 16.66% year-on-year to 2.198 billion yuan, raw material drug intermediates revenue decreased by 28.74% year-on-year to 6.165 billion yuan, and pharmaceutical business revenue decreased by 8.42% year-on-year to 1.15 billion yuan.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes